New York, Feb 25, 2026, 08:35 EST — Premarket
- BEAM picked up 0.7% before the bell, after having jumped almost 14% on Tuesday.
- The company pointed to an extended cash runway and also introduced a fresh program targeting PKU.
- Traders are watching for upcoming clinical updates linked to its liver pipeline.
Beam Therapeutics shares edged up 0.7% to $32.50 early Wednesday, building on Tuesday’s 14% surge that brought the stock to $32.29. (Investing)
Shares in the gene-editing firm snapped back after it posted a fourth-quarter profit and unveiled fresh financing, saying the new deal should carry its cash reserves through mid-2029. For investors wary of dilution and tight biotech funding, that’s a crucial detail. (GlobeNewswire)
Beam mapped out what it wants to hit in 2026 for its liver and blood disorder pipeline, promising an IND filing for BEAM-304 in phenylketonuria and fresh Phase 1/2 data from BEAM-302 by the close of Q1. (Gcs Web)
According to a regulatory filing, Sixth Street’s facility gives Beam up to $500 million in senior secured term loans, beginning with an initial $100 million. Unlocking more cash depends on milestones like FDA acceptance and approval for Beam’s BLA for risto-cel, along with a sales goal. The loan matures Feb. 24, 2033. (SEC)
The filing showed the loan carries a floating rate: 3-month SOFR plus 6.50%. SOFR, for reference, tracks overnight U.S. Treasury repo agreements.
Chief financial officer Sravan Emany called the new financing “significant flexibility and long-term, non-dilutive capital” for Beam. On the other side, Jeff Pootoolal, partner at Sixth Street, highlighted Beam’s work on programs he described as having “compelling clinical and commercial potential”—a combination that, he said, sets up the company for “long-term value creation.” (GlobeNewswire)
Beam shares ripped higher Tuesday, trading on strong volume as investors bought into the company’s case for shifting from platform work to late-stage programs—particularly for diseases that target the liver.
BofA bumped its price target on Beam up to $47 from $45, sticking with its buy call after the company rolled out pipeline updates and announced a fresh non-dilutive capital deal. (TipRanks)
Commercialization is also in the mix. The FDA recently cleared two cell-based gene therapies for sickle cell disease — Vertex and CRISPR Therapeutics’ Casgevy, as well as bluebird bio’s Lyfgenia — which sets a higher standard for those following on safety, manufacturing and patient access. (U.S. Food and Drug Administration)
But there’s a catch. Sixth Street’s loan leans on nearly all of Beam’s assets—intellectual property included. Unlocking the remaining tranches? That’s tied to whether Beam can meet clinical, regulatory, and commercial milestones. Any hiccup in trials can knock those off course. (Stock Titan)
Looking ahead, investors are zeroed in on Beam’s timeline for the BEAM-302 update, expected before the quarter wraps up. Management also offered some commentary on risto-cel during its post-earnings call, but more details are awaited. (Investing)
